Strategies to improve therapeutic efficacy in childhood acute myeloid leukemia.
- Author:
Xiao-Fan ZHU
1
Author Information
1. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China. Zhu_xf1981@yahoo.cn.
- Publication Type:Journal Article
- MeSH:
Child;
Humans;
Leukemia, Myeloid, Acute;
diagnosis;
drug therapy;
genetics;
mortality;
Leukemia, Promyelocytic, Acute;
drug therapy;
genetics
- From:
Chinese Journal of Contemporary Pediatrics
2014;16(2):108-110
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is a rare type of childhood acute leukemia, which has a worse prognosis than childhood acute lymphoblastic leukemia. Over the past decade, significant progress has been made in the treatment of childhood AML and the 5-year event-free survival rate may be as high as 70% in developed countries. This survival improvement is largely attributable to risk-stratified treatments, therapies tailored to individual patients based on the biological characteristics of the disease, and continuously improving supportive care. An accurate diagnosis is the prerequisite for risk stratification, prognostic evaluation and therapeutic decision making. How to reduce early mortality and thus improve overall survival, how to implement appropriate supportive treatment to reduce treatment-associated complications, and how to reduce treatment-related mortality are the key to the improvement of therapies for childhood acute myeloid leukemia.
